December 15, 2016
Canada's Cancer Research Society has announced the appointment of Max Fehlmann as its new President and Chief Executive Officer, effective January 16, 2017. Fehlmann founded the NEOMED Institute - a non-profit organization bridging the gap between academic innovations and the needs of the industry - and was its president since 2012. Before NEOMED, Fehlmann founded the Consortium Québécois pour la Découverte du Médicament (CQDM) in 2008, a public-private non-profit organization financing precompetitive research in drug discovery. He is a member of the Scientific Advisory Board of OncoAge in Nice, France, a member of the Board of Directors of RSSPQ in Montreal, and a member of the Board of Directors of CQDM, Montreal.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.